author-photo

Rahima Jamal

Université de Montréal

37

Papers

1409

Citations

Citation Trend

Filter By

Papers (37) Sort By

JournalConferenceOthers

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

2021 The Lancet Respiratory Medicine
Show All
- Source
- Cite
- Save
Citations (59)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Development of a HLA-B*58:01 Allele Screening System for Allopurinol-Induced Severe Cutaneous Adverse Reactions Detection

2020 IEEE Access
Show All
- Source
- Cite
- Save
Citations (0)
Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

2020 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (125)
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (2)
Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy for oropharyngeal carcinomas.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (11)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号